Financial Perspectives Inc Buys 41 Shares of argenx SE (NASDAQ:ARGX)

Financial Perspectives Inc grew its stake in shares of argenx SE (NASDAQ:ARGX) by 39.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 145 shares of the company’s stock after purchasing an additional 41 shares during the period. Financial Perspectives Inc’s holdings in argenx were worth $89,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of argenx by 35.9% in the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Lord Abbett & CO. LLC bought a new position in argenx during the third quarter valued at $88,339,000. Allspring Global Investments Holdings LLC grew its holdings in argenx by 38,152.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after purchasing an additional 143,834 shares during the period. Jennison Associates LLC grew its holdings in argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after acquiring an additional 55,617 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. JPMorgan Chase & Co. increased their target price on argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 price objective (up from $646.00) on shares of argenx in a research note on Thursday, November 21st. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and raised their price objective for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Truist Financial reaffirmed a “buy” rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company raised their price objective on argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research note on Thursday, December 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Stock Down 0.1 %

Shares of NASDAQ ARGX opened at $639.00 on Wednesday. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The firm has a market cap of $38.83 billion, a P/E ratio of -726.14 and a beta of 0.58. The company has a 50 day moving average of $640.74 and a 200 day moving average of $584.63.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.